CoChat
Cited by 228

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases

Open access
for the Italian Society of Locoregional Therapies in Oncology (SITILO), Cosimelli, M, Golfieri, R, Cagol, P P, Carpanese, L, Sciuto, R, Maini, C L, Mancini, R, Sperduti, I, Pizzi, G, Diodoro, M G, Perrone, M, Giampalma, E, Angelelli, B, Fiore, F, Lastoria, S, Bacchetti, S, Gasperini, D, Geatti, O, Izzo, F · 2010 · British Journal of Cancer

Abstract

BACKGROUND: This multi-centre phase II clinical trial is the first prospective evaluation of radioembolisation of patients with colorectal liver metastases (mCRC) who failed previous oxaliplatin- and irinotecan-based systemic chemotherapy regimens. METHODS: Eligible patients had adequate hepatic, haemopoietic and renal function, and an absence of major hepatic vascular anomalies and hepato-pulmonary shunting. Gastroduodenal and right gastric arteries were embolised before hepatic arterial administration of yttrium-90 resin microspheres (median activity, 1.7 GBq; range, 0.9-2.2). RESULTS: Of 50 eligible patients, 38 (76%) had received > or =4 lines of chemotherapy. Most presented with synchronous disease (72%), >4 hepatic metastases (58%), 25-50% replacement of total liver volume (60%) and bilateral spread (70%). Early and intermediate (>48 h) WHO G1-2 adverse events (mostly fever and pain) were observed in 16 and 22% of patients respectively. Two died due to renal failure at 40 days or liver failure at 60 days respectively. By intention-to-treat analysis using Response Evaluation Criteria in Solid Tumours, 1 patient (2%) had a complete response, 11 (22%) partial response, 12 (24%) stable disease, 22 (44%) progressive disease; 4 (8%) were non-evaluable. Median overall survival was 12.6 months (95% CI, 7.0-18.3); 2-year survival was 19.6%. CONCLUSION: Radioembolisation produced meaningful response and disease stabilisation in patients with advanced, unresectable and chemorefractory mCRC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.bjc.6605770

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 228

Metadata

Authors
for the Italian Society of Locoregional Therapies in Oncology (SITILO), Cosimelli, M., Golfieri, R., Cagol, P. P., Carpanese, L., Sciuto, R., Maini, C. L., Mancini, R., Sperduti, I., Pizzi, G., Diodoro, M. G., Perrone, M., Giampalma, E., Angelelli, B., Fiore, F., Lastoria, S., Bacchetti, S., Gasperini, D., Geatti, O., & Izzo, F.
Venue
British Journal of Cancer
Published
2010-07
Volume
103
Issue
3
Pages
324-331
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W1986389253
Cited by
228
References
5
FWCI
7.41
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. https://app.cochat.ai/papers/10.1038/sj.bjc.6605770
The paper
for the Italian Society of Locoregional Therapies in Oncology (SITILO), Cosimelli, M., Golfieri, R., Cagol, P. P., Carpanese, L., Sciuto, R., Maini, C. L., Mancini, R., Sperduti, I., Pizzi, G., Diodoro, M. G., Perrone, M., Giampalma, E., Angelelli, B., Fiore, F., Lastoria, S., Bacchetti, S., Gasperini, D., Geatti, O., & Izzo, F. (2010). Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6605770

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.